The FDA’s Proposed Rule on Laboratory-Developed Tests: Impacts on Clinical Laboratory Testing and Patient Care
Leslie Smith, Lisa A. Carricaburu, View ORCID ProfileJonathan R. Genzen
doi: https://doi.org/10.1101/2024.02.28.24303459
Leslie Smith
1ARUP Laboratories, Salt Lake City, UT, United States of America
Lisa A. Carricaburu
1ARUP Laboratories, Salt Lake City, UT, United States of America
Jonathan R. Genzen
1ARUP Laboratories, Salt Lake City, UT, United States of America
2Department of Pathology, University of Utah Health, Salt Lake City, UT, United States of America

Data Availability
The data that support the findings of this study are available from the corresponding author, JRG, upon reasonable request.
Posted March 01, 2024.
The FDA’s Proposed Rule on Laboratory-Developed Tests: Impacts on Clinical Laboratory Testing and Patient Care
Leslie Smith, Lisa A. Carricaburu, Jonathan R. Genzen
medRxiv 2024.02.28.24303459; doi: https://doi.org/10.1101/2024.02.28.24303459
Subject Area
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (219)
- Cardiovascular Medicine (3233)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13247)
- Forensic Medicine (19)
- Gastroenterology (890)
- Genetic and Genomic Medicine (5065)
- Geriatric Medicine (471)
- Health Economics (773)
- Health Informatics (3189)
- Health Policy (1129)
- Hematology (423)
- HIV/AIDS (1005)
- Medical Education (468)
- Medical Ethics (125)
- Nephrology (513)
- Neurology (4808)
- Nursing (254)
- Nutrition (716)
- Oncology (2482)
- Ophthalmology (702)
- Orthopedics (279)
- Otolaryngology (337)
- Pain Medicine (320)
- Palliative Medicine (89)
- Pathology (529)
- Pediatrics (1280)
- Primary Care Research (550)
- Public and Global Health (7369)
- Radiology and Imaging (1668)
- Respiratory Medicine (969)
- Rheumatology (473)
- Sports Medicine (415)
- Surgery (534)
- Toxicology (69)
- Transplantation (232)
- Urology (199)